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(p = 0.016). No significant correlations were found among 
cortisol levels and all parameters were investigated.
Conclusions Cortisol levels correlate with GH secretion 
and with many metabolic parameters in GHD children, while 
the metabolic effects during GHT are mainly due to GHT 
per se and less to cortisol reduction.
Keywords Growth hormone deficiency · Children · 
Cortisol
Introduction
The relationship between the growth hormone (GH)-
insulin like growth factor (IGF)-I system and the hypotha-
lamic–pituitary–adrenal (HPA) axis is complex and not 
univocal. Both a stimulatory and a neutral effect of IGF-I 
on the HPA axis have been demonstrated in in vitro models 
and in healthy subjects [1, 2], and the effect of the GH on 
the HPA axis, and specifically on the 11beta-hydroxysteroid 
dehydrogenases (11beta-HSD) isozymes, is widely docu-
mented. In peripheral tissues, corticosteroid hormone action 
is partially determined by the activity of 11beta-HSDs, two 
isozymes which interconvert hormonally active cortisol 
and inactive cortisone. 11beta-HSD2 inactivates cortisol 
to cortisone in the kidney, whilst 11beta-HSD1 performs 
the reverse reaction, activating cortisol from cortisone in 
the liver and adipose tissue. Neither GH nor IGF-I seem to 
affect 11beta-HSD2 activity, while GH inhibits cortisone 
to cortisol conversion through a reduction in 11beta-HSD1 
activity [3, 4]. Consequently, patients affected by growth 
hormone deficiency (GHD) demonstrate an increased corti-
sol/cortisone ratio and an alteration in 11beta-HSD1 activ-
ity in GHD could partially explain the increased cortisol 
production in key target tissues including liver and adipose 
Abstract 
Purpose Patients with growth hormone deficiency (GHD) 
demonstrate an increased cortisol/cortisone ratio which 
could potentially explain the metabolic features of GHD, 
while GH treatment (GHT) could increase the cortisol 
metabolism.
Methods In 35 children (27 M, mean age 10.1 years) with 
idiopathic GHD at baseline and after 12 months of GHT 
and in 25 controls, in addition to metabolic parameters, we 
assessed adrenal function by morning serum cortisol, its 
peak, and its area under the curve  (AUCCOR) during insulin 
tolerance test (ITT).
Results A cortisol peak <18 µg/dl was shown in 22 and 
31% of GHD children at baseline and after GHT, respec-
tively. At baseline, GHD children had lower fasting glucose 
(p < 0.001) and ISI-Matsuda (p = 0.042), with concomi-
tant higher Homa-IR (p = 0.006) and morning cortisol 
(p = 0.012) than controls. Morning cortisol was negatively 
correlated with GH (p < 0.001), fasting glucose (p < 0.001) 
and ISI-Matsuda (p < 0.001) and positively with Homa-
IR (p  =  0.010). Both cortisol peak and  AUCCOR were 
negatively correlated with GH (all p < 0.001) and ISI-
Matsuda (p = 0.016 and p = 0.001, respectively). After 
12 months of GHT, a significant increase in fasting glucose 
(p < 0.001), and Homa-IR (p = 0.011) was documented, 
with a concomitant decrease in morning cortisol (p = 0.002), 
 AUCCOR (p = 0.038), total (p = 0.003) and LDL-cholesterol 
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tissue, promoting insulin resistance and visceral adiposity, 
which are some of the phenotypic features of GHD [5, 6].
Conversely, in GH-treated patients, the GH-mediated 
increase in cortisol metabolism may unmask or precipitate 
adrenal insufficiency (AI) in patients with partial adreno-
corticotropic hormone deficiency commencing GH treat-
ment (GHT), through the negative effect on 11beta-HSD1 
activity and the reduction in cortisone to cortisol conver-
sion. In addition, the well-known beneficial effects of GHT 
on cardiovascular risk factors of GHD patients could also 
be an indirect effect via alterations in cortisol metabolism 
[7–9]. Therefore, this effect is always to be considered in 
patients affected by GHD both at diagnosis and during GHT. 
While evaluation of integrity of the HPA axis is essential 
in patients with organic GHD because it is well known that 
these patients may have additional pituitary hormone deficits 
[10] and GHT may unmask a central hypoadrenal state [11], 
weaker and quite discordant data exist on HPA function in 
patients with idiopathic GHD.
The aim of this study was to evaluate (1) the HPA func-
tion in children affected by idiopathic GHD at diagnosis and 
its potential change during GHT; (2) the role of serum corti-
sol in determining the metabolic features of GHD.
Materials and methods
We prospectively enrolled 35 children (27 M, 8 F; mean 
age 10.1 ± 1.4 years; range 6.9–11.6) affected by idiopathic 
GHD consecutively admitted to the Section of Endocri-
nology of the University of Palermo from January 2015 
to December 2016. Twenty-five healthy subjects, matched 
for sex (16 M, 9 F), age (mean age 9.4 ± 1.9 years; range 
5–11.4), stature, and pubertal status, were recruited as a con-
trol group at baseline among children referred for short stat-
ure. In this group, screening for short stature did not reveal 
endocrine disease and GHD was excluded. We excluded 
children affected by organic GHD, already known multiple 
pituitary hormone deficiency or receiving other hormonal 
replacement treatment. All patients, including the older ones, 
were in the first stage of sexual development according to the 
criteria of Marshall and Tanner [12], to avoid any interfer-
ence of puberty on the metabolic parameters analyzed, and 
these children maintained their prepubertal hormonal status 
during the observation period (i.e., FSH and LH <1 mU/ml, 
total testosterone and 17β-Estradiol <0.50 ng/ml and <5 pg/
ml in males and females, respectively).
GHD was diagnosed by the clinical, auxological, radio-
logical, and biochemical criteria of the GH Research Soci-
ety [13]. The auxological criteria included height more than 
two standard deviations (SD) below the mean and a growth 
velocity of 1 year before diagnosis more than 1 SD below 
the mean for age, or a decrease in height SD of more than 0.5 
over 1 year or, without severe short stature, a growth veloc-
ity more than 2 SD below the mean over 1 year or, finally, 
height more than 1.5 SD below the midparental height. As 
radiological criteria we considered a bone age delay, esti-
mated from an X-ray of the left wrist and hand and evaluated 
according to the methods of Greulich and Pyle, of at least 
1 year with respect to the chronological age [14]. Biochemi-
cally, GHD was diagnosed by the failure of GH to respond 
to glucagon stimulation test (GST) and insulin tolerance test 
(ITT), with GH peaks below 8 µg/l [15]. Neuroimaging, with 
magnetic resonance of the hypothalamic–pituitary region, 
was performed in all children with more severe GHD, i.e., 
with GH peak ≤3 μg/l, and when we suspected there was a 
multiple pituitary deficiency (overall in 11 children). Among 
them, no patient showed pituitary abnormalities.
All GHD children received GH once daily at bedtime 
with a pen injection system for at least 12 months. IGF-I 
levels and growth velocity allowed us to determine the GH 
dose. Specifically, the main targets were arbitrarily IGF-I 
levels between 0.5–1.5 SDS and growth velocity >0.5 
SDS. On average, in all patients, the initial daily dose of 
GH was 0.025 mg/Kg and it was gradually increased to 
0.027–0.028 mg/Kg from months 6 to 12, to achieve the 
abovementioned targets.
Study protocol
In all children at baseline, we measured body height 
[expressed as standard deviation, (SD)], growth velocity, 
body mass index (BMI), waist circumference (WC), and 
bone/chronological age ratio. GH secretion was evaluated 
by means of GST and ITT, performed on two different days. 
During GST, blood samples were collected at 0, 30, 60, 90, 
120, 150, 180, and 240 min after the injection of 30 μg/kg 
(up to 1000 μg) intramuscularly of glucagon (GlucaGen, 
NovoNordisk, Bagsvaerd, Denmark), for measurements of 
GH. ITT (0.1 U/kg of body weight of human Humulin R 
insulin) was performed in all children as a diagnostic test 
for GHD at baseline and at the same time to evaluate HPA 
function both at diagnosis and during GHT. Blood samples 
for GH, cortisol, and glucose were measured during ITT at 
baseline and at 30, 60, 90, and 120 min after insulin adminis-
tration; results were accepted with blood glucose lower than 
2.2 nmol/l (40 mg/dl). The areas under the curve (AUC) of 
GH  (AUCGH) during GST and ITT and cortisol  (AUCCOR) 
during ITT were calculated using the trapezoidal rule.
On a different day, a blood sample was drawn after an 
overnight fast for the measurement of hemoglobin A1c 
(HbA1c) and IGF-I concentrations. This sample also served 
as the baseline sample for an oral glucose tolerance test 
(OGTT). Blood samples were collected every 30 min for 
2 h for glucose and insulin measurements. AUC of glucose 
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 (AUCGLU) and insulin  (AUCINS) during OGTT was calcu-
lated using the trapezoidal rule.
HPA function was assessed through the morning adreno-
corticotropic hormone (ACTH) and cortisol levels and the 
cortisol response to ITT, by considering both the highest 
value during the test, i.e., cortisol peak and the  AUCCOR. 
We considered a morning basal cortisol value of <3 µg/dl 
as already diagnostic for AI, while we excluded the diagno-
sis with a basal cortisol value >18 µg/dl. A serum cortisol 
increase to at least 18 µg/dl during ITT was used as a crite-
rion for a functioning HPA.
After the diagnosis of GHD was made, in GHD children 
in addition to auxological parameters and IGF-I measure-
ment we performed both ITT (for cortisol) and OGTT (for 
glucose and insulin) after 12 months of GHT. As surrogate 
estimates of insulin sensitivity, we considered the homeosta-
sis model assessment estimate of insulin resistance (Homa-
IR) [16] and the insulin sensitivity index (ISI), a composite 
index derived from the OGTT and validated by Matsuda and 
DeFronzo [17], while as estimates of insulin secretion we 
considered fasting insulin and  AUCINS. In the control group, 
these evaluations were performed only at baseline.
The institutional Ethics Committee of the University of 
Palermo approved this study. At the time of hospitalization, 
an informed consent for the scientific use of the data was 
obtained from both the participants and their parents.
Hormone and biochemical assays
All biochemical data were collected after overnight fast-
ing. Glucose and lipids were measured in the centralized 
accredited laboratories of the University of Palermo with the 
standard methods. Serum insulin was measured by ELISA 
(DRG Instruments GmbH, Germany). The sensitivity of 
the method was 1 IU/ml. The normal insulin range (IU/ml) 
was 5–19. HbA1c levels were determined by HPLC with 
an ion-exchange resin (HA8121, Hi-AutoA1c, Menarini, 
Florence, Italy). Serum GH levels were measured by means 
of immunoradiometric assay using commercially avail-
able kits (Radim, Italy). The sensitivity of the assay was 
0.04 µg/l. The intra- and inter-assay coefficients of variation 
(CV) were 2.5–3.9 and 3.8–5.0%, respectively. We reported 
GH concentrations in µg/l of IS 98/574. Serum IGF-I levels 
were measured by means of a chemiluminescent immuno-
metric assay (Immulite 2000; Diagnostic Products Corp., 
Los Angeles, CA, USA) using murine monoclonal anti-
IGF-I antibodies. The standards were calibrated against the 
World Health Organization second IS 87/518. The sensitiv-
ity of the method was 1.9 µg/l. The intra- and inter-assay 
CVs were 2.3–3.9 and 3.7–8.1%, respectively. Values were 
expressed as SD according to the normative data provided 
by the manufacturer. Serum cortisol was evaluated using 
the electrochemiluminescent (ECLIA) automated method 
access (Beckman Coulter, Brea, CA, USA). ACTH levels 
were detected by electrochemiluminescence immunoassay 
(Elecsys, Roche, Milan).
Statistical analysis
The Statistical Packages for Social Sciences SPSS version 
19 was used for data analysis. Baseline characteristics were 
presented as mean ± SD for continuous variables (normality 
of distribution for the quantitative variables was assessed 
with the Kolmogorov–Smirnov test); rates and propor-
tions were calculated for categorical data. The differences 
between groups were evaluated with the t test. Pearson’s 
correlation was performed among continuous variables. A p 
value <0.05 was considered statistically significant.
Results
Clinical and hormonal parameters
The clinical and hormonal parameters of control subjects, 
GHD children at diagnosis and after 12 months of GHT are 
shown in Table 1.
No significant difference in height and bone/chronologi-
cal age ratio between GHD children at baseline and control 
subjects was found. Conversely, GHD children at baseline 
showed significantly lower growth velocity (−3.1 ± 1.8 
vs. −1.1 ± 1.0 SD; p = 0.023), IGF-I levels (88.4 ± 26.7 
vs. 198.4  ±  53.2  µg/l; p  <  0.001 or −0.74  ±  0.31 vs. 
1.30 ± 0.46 SD; p < 0.001), GH peak and  AUCGH after ITT 
(4 ± 1.4 vs. 12.9 ± 2.8 µg/l; p < 0.001 and 308 ± 168 vs. 
962 ± 297 µg/l; p < 0.001) and GH peak and  AUCGH after 
GST (4.2 ± 3.3 vs. 11.5 ± 6.6 µg/l; p < 0.001 and 282 ± 154 
vs. 712 ± 368 µg/l; p = 0.001) than controls, with concomi-
tant higher BMI (−1.2 ± 0.9 vs. −2.1 ± 0.6 SD; p < 0.001) 
and WC (62.1 ± 7.5 vs. 57.7 ± 4.3 cm; p = 0.015).
In the GHD group, growth significantly increased after 
12 months of GHT (height: −1.5 ± 0.7 vs. −2.2 ± 0.6 
SD; p < 0.001; growth velocity: 1.6 ± 0.9 vs. −3.1 ± 1.8 
SD; p  <  0.001), with a concomitant increase in IGF-I 
(213.9 ± 122.1 vs. 88.4 ± 26.7 µg/l; p < 0.001 or 1.45 ± 0.75 
vs. −0.74 ± 0.31 SD; p < 0.001) and a significant decrease 
in WC (59.6 ± 7.9 vs. 62.1 ± 7.5 cm; p = 0.032). No signifi-
cant change was documented for BMI and bone/chronologi-
cal age ratio (Table 1).
Metabolic parameters
The metabolic parameters of control subjects, GHD chil-
dren at diagnosis, and after 12 months of GHT are shown 
in Table 1.
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All GHD children at baseline had normal fasting glucose 
levels, although they were significantly lower than controls 
(3.89 ± 0.40 vs. 4.49 ± 0.41 mmol/l; p < 0.001). In addi-
tion, GHD children showed higher fasting insulin (6.3 ± 3.2 
vs. 3.1 ± 2 IU/ml; p = 0.001), Homa-IR (1.19 ± 0.65 vs. 
0.64 ± 0.43; p = 0.006), and lower ISI-Matsuda (11.5 ± 5 
vs. 15.8 ± 7.9; p = 0.042) than controls. No significant dif-
ference was found in  AUCGLU,  AUCINS, HbA1c, and lipid 
profile between GHD children at baseline and control sub-
jects (Table 1).
After 12 months of GHT, a significant increase in fasting 
glucose (4.63 ± 0.21 vs. 3.89 ± 0.40 mmol/l; p < 0.001), 
fasting insulin (12.1 ± 2.7 vs. 6.3 ± 3.2 IU/ml; p = 0.021), 
and Homa-IR (2.48 ± 0.53 vs. 1.19 ± 0.65; p = 0.011) 
was documented, although all children maintained normal 
glucose tolerance. No significant difference was found in 
 AUCGLU,  AUCINS, HbA1c, and ISI-Matsuda.
Total (3.92 ± 0.98 vs. 4.16 ± 0.85 mmol/l; p = 0.003) 
and LDL-cholesterol (1.97 ± 0.81 vs. 2.17 ± 0.70 mmol/l; 
p = 0.016) significantly decreased after 12 months of GHT, 
Table 1  Clinical, hormonal, 
and metabolic parameters of 
control subjects and GHD 
children at diagnosis (baseline) 
and after 12 months of GH 
treatment
Data are presented as rates and proportions for the categorical data and as mean ± standard deviation (SD) 
for the continuous variables
BMI body mass index, WC waist circumference, ITT insulin tolerance test, GST glucagon stimulation test, 
AUC area under the curve, AUCGLU AUC of glucose during OGTT, AUCINS AUC of insulin during OGTT, 
p difference between parameters of control subjects and GHD children at baseline, p* difference between 
parameters at baseline and after 12 months of treatment in GHD group
Control group baseline
(N. 25)
GHD 
baseline
(N. 35)
GHD 
12 months
(N. 35)
p p*
Gender 0.125
 Males 16 (64) 27 (77)
 Females 9 (36) 8 (23)
Age (years) 9.4 ± 1.9 10.1 ± 1.4 – 0.149
Height (SD) −2.2 ± 0.4 −2.2 ± 0.6 −1.5 ± 0.7 0.893 <0.001
Growth velocity (cm/year) 4.8 ± 2.1 2.7 ± 1.5 8.6 ± 2.9 0.003 <0.001
Growth velocity (SD) −1.1 ± 1.0 −3.1 ± 1.8 1.6 ± 0.9 0.023 <0.001
BMI (Kg/m2) 15.1 ± 1.5 16.3 ± 2.5 16.6 ± 2.2 0.028 0.985
BMI (SD) −2.1 ± 0.6 −1.2 ± 0.9 −1.2 ± 0.8 <0.001 0.187
WC (cm) 57.7 ± 4.3 62.1 ± 7.5 59.6 ± 7.9 0.015 0.032
Bone/chronological age ratio 0.88 ± 0.13 0.84 ± 0.11 0.89 ± 0.11 0.277 0.248
IGF-1 (µg/L) 198.4 ± 53.2 88.4 ± 26.7 213.9 ± 122.1 <0.001 <0.001
IGF-1 (SD) 1.30 ± 0.46 −0.74 ± 0.31 1.45 ± 0.75 <0.001 <0.001
GH peak after ITT (µg/l) 12.9 ± 2.8 4 ± 1.4 – <0.001 –
AUCGH during ITT (µg/l) 962 ± 297 308 ± 168 – <0.001 –
GH peak after GST (µg/l) 11.5 ± 6.6 4.2 ± 3.3 – <0.001 –
AUCGH during GST (µg/l) 712 ± 368 282 ± 154 – 0.001 –
Glucose metabolism
 Fasting glucose (mmol/l) 4.49 ± 0.41 3.89 ± 0.40 4.63 ± 0.21 <0.001 <0.001
 AUCGLU (mmol/l) 726 ± 112 700 ± 101 763 ± 73 0.471 0.612
 HbA1c (%) 5.3 0.4 5.1 0.3 5.2 ± 0.3 0.136 0.464
Lipid profile
 Total cholesterol (mmol/l) 4.07 ± 0.43 4.16 ± 0.85 3.92 ± 0.98 0.620 0.003
 HDL-cholesterol (mmol/l) 1.78 ± 0.32 1.70 ± 0.39 1.60 ± 0.33 0.461 0.209
 LDL-cholesterol (mmol/l) 2.02 ± 0.54 2.17 ± 0.70 1.97 ± 0.81 0.488 0.016
 Triglycerides (mmol/l) 1.37 ± 0.40 1.45 ± 0.43 1.74 ± 0.82 0.412 0.212
Insulin secretion indexes
 Fasting insulin (IU/ml) 3.1 ± 2 6.3 ± 3.2 12.1 ± 2.7 0.001 0.021
 AUCINS (IU/ml) 3976 ± 2156 3318 ± 1666 3173 ± 1764 0.299 0.872
Insulin sensitivity indexes
 Homa-IR 0.64 ± 0.43 1.19 ± 0.65 2.48 ± 0.53 0.006 0.011
 ISI-Matsuda 15.8 ± 7.9 11.5 ± 5 8.8 ± 2.6 0.042 0.066
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while no change in HDL cholesterol and triglycerides was 
documented (Table 1).
Adrenal function
The HPA evaluation of control subjects, GHD children at 
diagnosis and after 12 months of GHT are shown in Table 2.
Morning serum cortisol levels,  AUCCOR, and cortisol 
peak during ITT proved to be positively and strongly cor-
related with one another both in the totality of children and 
separately in GHD children at both baseline and after GHT 
(all p < 0.010; data not shown).
Overall, based on morning cortisol levels and consider-
ing 3 µg/l as the cut-off value for diagnosing AI, no subject 
showed overt AI at both baseline and after 12 months of 
GHT.
Based on cortisol peak levels, a subnormal cortisol 
response (i.e., <18 µg/dl) to ITT was shown in 10 out of 60 
children [2 out of 25 controls (8%) and 8 out of 35 GHD chil-
dren (22%), with a mean cortisol peak of 17.7 and 13.8 µg/l, 
respectively] at baseline, while 11 out of 35 GHD children 
(31%) showed a cortisol peak value lower than 18 µg/l (mean 
cortisol peak of 12.1 µg/l) after 12 months of GHT, without 
any typical clinical signs or symptoms of AI.
At baseline, GHD children showed higher morning serum 
cortisol (11.7 ± 2.8 vs. 9.4 ± 2.8 µg/l; p = 0.012) and lower 
ACTH levels (18.4 ± 6.3 vs. 22 ± 6.1 pg/ml; p = 0.041), 
while no differences in serum sodium (p = 0.709) and potas-
sium (p = 0.112), cortisol peak (p = 0.535) and  AUCCOR 
(p = 0.128) during ITT were found (Table 2).
After 12 months of GHT, a significant decrease in morn-
ing serum cortisol (8.9 ± 2.3 vs. 11.7 ± 2.8 µg/l; p = 0.002) 
and  AUCCOR (1489 ± 464 vs. 1868 ± 878 µg/l; p = 0.038) 
was documented, without significant change in serum 
sodium and potassium, and in cortisol peak during ITT 
(Table 2).
The correlations among cortisol secretion and the clini-
cal, hormonal, and metabolic parameters in GHD children at 
baseline and after 12 months of GHY are shown in Table 3 
and Fig. 1.
At baseline, in GHD children, morning serum cortisol 
levels proved to be significantly and negatively correlated 
with GH peak (r −0.664; p < 0.001) and  AUCGH (r −0.631; 
p < 0.001) during a/the stimulus test, fasting glucose (r 
−0.664; p < 0.001), and ISI-Matsuda (r −0.689; p < 0.001), 
while they were positively correlated with fasting insulin 
(r 0.483; p = 0.011) and Homa-IR (r 0.485; p = 0.010). 
Similarly, both cortisol peak and  AUCCOR at baseline were 
negatively correlated with GH peak (r −0.651; p < 0.001 
and r −0.722; p < 0.001, respectively),  AUCGH (r −0.603; 
p < 0.001 and r −0.662; p < 0.001, respectively) and ISI-
Matsuda (r −0.468; p = 0.016 and r −0.593; p = 0.001, 
respectively), while  AUCCOR also positively correlated with 
Homa-IR (r 0.386; p = 0.047). These correlations were not 
confirmed when we analyzed separately the control group 
at baseline (data not statistically significant and not shown). 
No significant correlation was found between ACTH levels 
and the clinical, hormonal, and metabolic parameters neither 
in GHD nor in controls (data not shown).
After 12 months of GHT, no significant correlations 
were found among cortisol levels and all parameters were 
investigated, with the exception of a slight negative correla-
tion between cortisol peak and fasting glucose (r −0.589; 
p = 0.044). No significant correlations were found between 
cortisol and IGF-I levels (data not shown).
Discussion
This study showed that the HPA function is strongly cor-
related with GH secretion and with many metabolic aspects 
of overt GHD. GHD children showed higher cortisol levels 
than controls and these levels are related to the insulin sensi-
tivity degree. Conversely, GHT leads to a slight reduction in 
cortisol levels and to a loss of relationship between cortisol 
and metabolic parameters.
Table 2  Adrenal function of control subjects and GHD children at diagnosis (baseline) and after 12 months of GH treatment
Data are presented as mean ± standard deviation (SD)
ITT insulin tolerance test, AUCCOR area under the curve of serum cortisol during ITT, ACTH adrenocorticotropic hormone, p difference in 
parameters between control subjects and GHD children at baseline, p* difference in parameters between baseline values and after 12 months of 
treatment in GHD group
Control group base-
line (N. 25)
GHD baseline (N. 35) GHD 12 months 
(N. 35)
p p*
Serum sodium (mEq/l) 139.2 ± 2.6 139.5 ± 2.6 140.2 ± 1.8 0.709 0.154
Serum potassium (mEq/l) 4.3 ± 0.2 4.4 ± 0.3 4.3 ± 0.3 0.112 0.066
Morning serum cortisol (µg/l) 9.4 ± 2.8 11.7 ± 2.8 8.9 ± 2.3 0.012 0.002
Serum cortisol peak during ITT (µg/l) 19 ± 1.1 19.8 ± 3.9 18.6 ± 3.5 0.535 0.234
AUCCOR during ITT (µg/l) 1606 ± 379 1868 ± 878 1489 ± 464 0.128 0.038
Morning serum ACTH (pg/ml) 22 ± 6.1 18.4 ± 6.3 18.7 ± 6 0.026 0.071
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GHD patients potentially represent a population at risk 
of developing functional alterations of the HPA axis up to 
overt AI. Indeed, both GHD condition per se, due to poten-
tial concomitant multiple pituitary hormone deficiency, and 
GHT, due to the GH impact on cortisol metabolism, can be 
potentially associated with AI [10, 18]. However, there are 
discordant data in the literature about the HPA function in 
GHD and during GHT. AI is frequently observed in GHD 
patients with genetic or structural alterations [19, 20]. Gia-
voli et al. evaluated the HPA axis in patients with adult-onset 
GHD due to surgically treated pituitary tumors by means of 
morning serum cortisol levels as well as cortisol responses 
to stimulation test before and during GHT. The authors 
demonstrated central AI in 9 out of 11 patients, concluding 
that reassessment of HPA function in organic GHD patients 
during GHT is mandatory [11]. Indeed, it is widely known 
that GH influences cortisol metabolism by modulating the 
activity of 11beta-HSD1, which is the main target of cortisol 
modulation by GH [6, 8, 21]. However, few and sometimes 
discordant data about HPA axis evaluation during GHT in 
children with idiopathic GHD are available in the literature.
In ten consecutive children with idiopathic GHD, Giavoli 
et al. demonstrated that no child became AI during GHT, 
without differences in cortisol peak after a provocative test 
from baseline to a mean of 12 months of GHT. These authors 
concluded that probably only in patients with organic multi-
ple pituitary hormone deficiency GHD masks the presence 
of a hidden central AI and that the HPA function evalua-
tion in children with idiopathic GHD is not required during 
the follow-up [22]. Similarly, other authors suggested that 
patients with GHD without abnormalities on MRI probably 
do not need HPA testing. Indeed, among a relatively large 
number of children with idiopathic GHD whose HPA axis 
was evaluated, none had AI before GHT [23]. Conversely, in 
one of the largest series involving more than 2000 children 
with GHD, August et al. showed that about 11% of those 
with idiopathic GHD had central AI, suggesting, however, 
that AI is relatively uncommon in children without anatomic 
abnormalities [24].
Our data are partially in agreement with these studies. 
Indeed, we found that about 22% of GHD children at diagno-
sis showed a cortisol peak during ITT lower than the widely 
accepted cut-off (i.e., 18 µg/l), although none of the patients 
were symptomatic for AI, while when we considered the 
morning serum cortisol levels no child showed values lower 
than 3 µg/l.
However, it should be noted that ACTH deficiency is gen-
erally uncommon in children with idiopathic GHD and it 
has rarely been reported in the absence of organic lesions. 
In our hypothesis, despite the cortisol peak did not reach 
the established cut-off of 18 µg/dl for a while, the increase 
in cortisol levels from baseline to peak during ITT was very 
significant (up to 70%) and therefore it could be considered 
quite satisfactory both in the two controls and in the eight 
GHD children suspected of having AI. For these reasons, we 
decided not to treat these children for AI and clinically fol-
low them. Indeed, the biochemical criteria used to diagnose 
AI take into account only a fixed cut-off and do not consider 
the size of the change of cortisol from the baseline value to 
the peak reached during the stimulation test, even if below 
the established cut-off.
Our data are in agreement with another study which 
showed subnormal cortisol response to ITT in 10 out of 25 
children (40%) with idiopathic GHD [25]. Similarly, Lange 
et al. reported in a group of adults previously treated for idio-
pathic childhood-onset GHD a percentage of 44% of asymp-
tomatic AI. The authors concluded that HPA axis evaluation 
Table 3  Correlations (univariate analysis) between cortisol secretion 
(morning serum cortisol, peak during ITT and AUC, respectively) 
and the clinical, hormonal, and metabolic parameters in GHD chil-
dren at baseline and after 12 months of GH treatment
ITT insulin tolerance test, AUCGH AUC of GH during ITT, BMI body 
mass index, WC waist circumference
Independent variables Dependent variable: morning serum 
cortisol
Baseline 12 months
r p r p
GH peak after ITT (µg/l) −0.664 <0.001 – –
AUCGH during ITT (µg/l) −0.631 <0.001 – –
BMI (SD) 0.274 0.117 0.142 0.588
WC (cm) 0.068 0.724 0.118 0.663
Fasting glucose (mmol/l) −0.664 <0.001 −0.120 0.710
Fasting insulin (IU/ml) 0.483 0.011 0.262 0.410
Homa-IR 0.485 0.010 0.251 0.431
ISI-Matsuda −0.689 <0.001 −0.366 0.298
Serum cortisol peak during ITT
 GH peak after ITT (µg/l) −0.651 <0.001 – –
 AUCGH during ITT (µg/l) −0.603 <0.001 – –
 BMI (SD) 0.250 0.154 0.331 0.194
 WC (cm) 0.031 0.874 0.045 0.868
 Fasting glucose (mmol/l) −0.185 0.288 −0.589 0.044
 Fasting insulin (IU/ml) 0.277 0.161 0.144 0.656
 Homa-IR 0.367 0.060 0.318 0.314
 ISI-Matsuda −0.468 0.016 −0.197 0.585
AUCCOR during ITT
 GH peak after ITT (µg/l) −0.722 <0.001 – –
 AUCGH during ITT (µg/l) −0.662 <0.001 – –
 BMI (SD) 0.306 0.078 0.062 0.812
 WC (cm) 0.022 0.910 0.240 0.370
 Fasting glucose (mmol/l) −0.254 0.140 −0.484 0.111
 Fasting insulin (IU/ml) 0.289 0.144 0.079 0.807
 Homa-IR 0.386 0.047 0.239 0.454
 ISI-Matsuda −0.593 0.001 −0.004 0.992
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at regular intervals is essential in these patients and that 
GHD may represent a predisposing factor for AI [18].
The discrepancy between these studies is probably due to 
the heterogeneity of the diagnostic criteria and of the tests 
used to assess HPA function. Indeed, although the diagnosis 
of overt AI is generally simple, the diagnosis of central AI, 
particularly in subjects with partial deficiency, or the iden-
tification of asymptomatic patients with subtle AI, is still 
a challenge. Patients with slight dysfunctions are at risk of 
developing adrenal crisis since their HPA does not appro-
priately react to stress. Therefore, identification of patients 
potentially at risk of AI is mandatory. There is consider-
able debate regarding the best test of the diagnosis of AI. 
Optimally, a screening test would be economic, convenient, 
and safe and it would have high sensitivity and specificity. 
Unfortunately, to date, no test for AI diagnosis meets all 
of these criteria. Response to ITT is considered the gold 
standard in the evaluation of the integrity of the HPA axis, 
although its validity has been questioned [26–28] and in 
patients with idiopathic multiple pituitary hormone deficien-
cies the low-dose short adrenocorticotropin test seemed to be 
equivalent to ITT [29–31] or even superior to the standard-
dose corticotrophin test in the diagnosis of central AI [32]. 
Specifically, the reliability of the test used to evaluate HPA 
function in GHD patients was tested by Maghnie et al. The 
authors concluded that none of the tests can be considered 
completely reliable for establishing the presence of adrenal 
insufficiency, although ITT seems to be the most sensitive 
for detecting subclinical or partial AI [33]. In agreement, 
we used ITT to evaluate the HPA axis in GHD children. 
Although we showed good correlation between morning 
serum cortisol and its peak during ITT, it is widely demon-
strated that the baseline morning serum cortisol concentra-
tion has limited predictive power in differentiating between 
normal and impaired HPA function [27, 28, 34]. In agree-
ment with these observations, our data showed that morning 
cortisol evaluation cannot be considered a reliable indicator 
of AI in children with GHD because the capacity of morn-
ing cortisol to diagnose AI differs from that of the cortisol 
peak during ITT; that is to say, with the cortisol peak we 
can diagnose a percentage of potential AI that cannot be 
diagnosed with morning cortisol. Indeed, all GHD children 
who at baseline showed a cortisol peak less than 18 µg/dl 
had a baseline cortisol value greater than 3 µg/dl. In addi-
tion, when we calculated the AUC of cortisol during ITT, 
although it showed good direct correlation with both morn-
ing cortisol and cortisol peak during ITT, it did not prove to 
have greater utility than morning serum cortisol or cortisol 
peak. Notably, morning cortisol levels were higher in GHD 
children than in controls, but in the GHD group we found a 
Fig. 1  Correlations (univariate analysis) between serum morning cortisol secretion and GH peak (µg/l) during ITT, ISI-Matsuda, fasting glu-
cose (mmol/l), and fasting insulin (IU/ml) in GHD children at baseline
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higher prevalence of cortisol peak less than the established 
cut-off of 18 µg/dl. This finding, confirms the lack of utility 
of basal cortisol levels as a diagnostic test for AI.
All three of these cortisol parameters in GHD children 
at diagnosis demonstrated a good negative correlation with 
GH secretion (both GH peak and  AUCGH during stimulation 
test) and with insulin sensitivity. Specifically, cortisol levels 
seem to be higher in concomitance with lower GH levels. 
Indeed, GHD children showed significantly higher morning 
serum cortisol levels and higher, although not statistically 
significant, peak and AUC of cortisol levels than controls. 
Conversely, we found a lack of correlation between corti-
sol and GH values in controls. We could speculate that the 
lower fasting glucose levels secondary to GHD, although 
still within the normal range, may lead to a rise in cortisol 
levels. Indeed, a negative correlation between morning fast-
ing cortisol levels and fasting glucose was demonstrated at 
baseline in GHD children and not in controls. These data 
can further confirm and explain what was previously stated 
about the lack of reliability of morning serum cortisol as 
diagnostic test for AI if compared to cortisol peak in GHD.
In turn, the higher cortisol levels in GHD children may 
determine an increase in fasting insulin and a decrease in 
insulin sensitivity (as demonstrated by the higher Homa-
IR and lower ISI-Matsuda in GHD than controls). The lat-
ter two are typical features of GHD, in concomitance with 
the evidence of higher BMI and WC, probably secondary 
to GHD per se, which in turn can worsen insulin sensitiv-
ity reduction. Indeed, overt GHD shows many features of 
metabolic syndrome [35], including abdominal obesity and 
insulin resistance, which are also typical of the conditions of 
cortisol excess [36]. This finding could lead us to speculate 
that higher cortisol levels, secondary to an increased activ-
ity of 11beta-HSD1 in GHD patients, may play a role in the 
development of the abovementioned clinical features.
However, if an overt metabolic syndrome is more easily 
associated with GHD in adult patients, probably because of 
the diagnostic and therapeutic delay, the metabolic altera-
tions are less manifest in children and just a trend to a worse 
metabolic profile, such as lower insulin sensitivity degree 
or greater visceral obesity, may happen and the metabolic 
syndrome may be not yet clearly manifested, as shown in 
our study.
Though our data showed a correlation among corti-
sol levels and many metabolic aspects of overt GHD, this 
relationship seems to be lost after GHT. Indeed, controver-
sial data exist in the literature on the effects of GHT on 
HPA function. Weaver et al. studied 19 adult hypopituitary 
patients who were receiving conventional hydrocortisone 
replacement during a 6-month period of GHT. The authors 
demonstrated that GHT in hypopituitary adults is associated 
with an apparent reduction in availability of administered 
hydrocortisone and concluded that the changes in cortisol 
metabolism suggest that GH may directly or indirectly mod-
ulate the activity of 11beta-HSD1 [7]. Recently, in a multi-
center study that evaluated the HPA axis before and during 
6 months of GHT therapy in 72 GHD patients, cortisol levels 
significantly decreased in patients already having multiple 
pituitary hormone deficiencies at baseline, and it decreased, 
although it remained within the normal range, in patients 
with isolated GHD [37].
Our data are partially in agreement with these studies. 
Indeed, we showed a significant decrease in morning serum 
cortisol and in  AUCCOR during 12 months of GHT, with a 
trend to decrease, although not significant, in cortisol peak, 
and without change in serum sodium and potassium. In addi-
tion, despite the slight decrease in cortisol peak observed, 
after 12 months of GHT a higher percentage of children 
than baseline (31 vs. 22%) showed a cortisol peak less than 
18 µg/l, without any typical signs or symptoms of AI. Prob-
ably, also in the absence of hypothalamic-pituitary organic 
pathologies, as in our cohort of children, the modulation 
exerted by GHT leads only to a slight decrease in corti-
sol levels by reducing the activity of 11beta-HSD1, with-
out clinical consequences. Probably, the possible effect in 
decreasing cortisol binding globulin (CBG) levels cannot be 
ruled out for cortisol reduction during GHT, although this 
effect was not always confirmed [11]. However, despite the 
reduction in basal cortisol and  AUCCOR during GHT and 
the increased prevalence of suspected AI, even in this case, 
as already noted at baseline, the increase in cortisol levels 
from baseline to peak during ITT was very pronounced (up 
to 90%) even in the 11 children suspected of having AI and 
we decided to keep patients in follow-up without initiating 
glucocorticoid treatment. However, it is to be noted that the 
lack of significant change in ACTH levels after GHT (lack 
of feed-back) could lead us to hypothesize that there may 
be a partial ACTH deficiency which have influenced GH 
peak at diagnosis and it could potentially explain the higher 
prevalence of AI in GHD than controls. These data reinforce 
the awareness that diagnosis of central AI, particularly in 
children with suspected partial deficiency, or the identifica-
tion of asymptomatic patients with subtle AI, is difficult and 
still a challenge.
In our study, GHT led to an improvement in auxological 
parameters and IGF-I levels with a concomitant decrease 
in WC, as expected. In addition, we found higher fasting 
glucose and insulin levels with higher insulin resistance, 
as demonstrated by the increase in Homa-IR and the trend 
to decrease of ISI-Matsuda. This trend to impairment in 
glucose metabolism during GHT has often been previously 
demonstrated [38, 39]. Indeed, it is widely known that GHT 
leads to a decrease in insulin sensitivity and alteration in 
insulin secretion even without overt changes in glucose 
tolerance, and the current study confirms this finding, as 
demonstrated by the unchanged HbA1c levels. In addition, 
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a slight improvement in lipid profile was demonstrated after 
12 months of GHT and this finding is in agreement with 
our previous studies [15, 40]. Overall, in our opinion, the 
metabolic changes which occur after GHT are likely sec-
ondary to the counter-regulating effects of GH (the increase 
in glucose and insulin levels and the reduction in insulin 
sensitivity) and to its lipolytic effect (demonstrated by the 
improvement in lipid profile and reduction in WC). In addi-
tion, the impact of GHT on a series of adipokines known 
to have a metabolic role [41], could explain the lack of a 
direct relationship between cortisol levels and metabolic 
parameters during GHT. In concomitance with a slight 
increase in glucose levels, and mediated by the known 
GH effect on cortisol metabolism, cortisol levels tended 
to decrease, although without determining overt AI, lead-
ing to a loss of its relationship with metabolic parameters. 
Therefore, the metabolic effect observed during GHT must 
be considered to be independent of any change in cortisol 
metabolism [7–9]. These data are in agreement with the 
study performed by Yuen et al., who demonstrated no cor-
relation between the change in metabolic parameters and 
cortisol levels in adult GHD patients during GHT [42].
In our opinion, the strength of our study was the use 
of the same test (i.e., ITT) in all patients in concomitance 
with full metabolic evaluation. Conversely, the limits were 
certainly represented by the relatively small sample size, 
the limited period of observation and the lack of data for 
the control group after 12 months of follow-up. Indeed, we 
cannot exclude with certainty that the cortisol change after 
12 months are due to some other factor, in addition to GHT. 
However, in our opinion, it is very difficult to perform a full 
metabolic and hormonal evaluation, through OGTT and 
ITT, in healthy children during a follow-up of 12 months.
In conclusion, cortisol levels correlate well with GH 
secretion and with many metabolic parameters, so they 
could have a potential role in the development of meta-
bolic alterations associated with GHD in children. Con-
versely, the metabolic effects during GHT are mainly due 
to GHT per se and less to cortisol reduction. GHT may 
potentially lead to a reduction in cortisol levels also in 
children with idiopathic GHD and endocrinologists should 
be mindful of this phenomenon when starting treatment 
with GH. Indeed, most children with multiple hormone 
deficiency or with etiology other than idiopathic GHD are 
frequently subject to a full endocrine evaluation, whereas 
wrongly this is not the case for patients with idiopathic 
GHD. Larger studies, with longer periods of follow-up 
of GHT, will be able to confirm the results of this study.
Compliance with ethical standards 
Conflict of interest All authors declare that there is no conflict of 
interest that could be perceived as prejudicing the impartiality of the 
research reported.
Funding This research did not receive any specific grant from any 
funding agency in the public, commercial or not-for-profit sector.
Ethical approval All procedures performed in studies involving 
human participants were in accordance with the ethical standards of 
the institutional and/or national research committee and with the 1964 
Helsinki declaration and its later amendments or comparable ethical 
standards.
Informed consent At the time of hospitalization, an informed con-
sent for the scientific use of the data was obtained from individual 
participants included in the study and their parents.
References
 1. Le Roy C, Li JY, Stocco DM, Langlois D, Saez JM (2000) Regu-
lation by adrenocorticotropin (ACTH), angiotensin II, transform-
ing growth factor-beta, and insulin-like growth factor I of bovine 
adrenal cell steroidogenic capacity and expression of ACTH 
receptor, steroidogenic acute regulatory protein, cytochrome 
P450c17, and 3beta-hydroxysteroid dehydrogenase. Endocrinol-
ogy 141(5):1599–1607
 2. Gianotti L, Ramunni J, Lanfranco F, Maccagno B, Giordano R, 
Broglio F, Maccario M, Muller EE, Ghigo E, Arvat E (2001) 
Recombinant human IGF-I does not modify the ACTH and corti-
sol responses to hCRH and hexarelin, a peptidyl GH secretagogue, 
in humans. J Endocrinol Invest 24(2):67–71
 3. Ricketts ML, Verhaeg JM, Bujalska I, Howie AJ, Rainey WE, 
Stewart PM (1998) Immunohistochemical localization of type 1 
11beta-hydroxysteroid dehydrogenase in human tissues. J Clin 
Endocrinol Metab 83(4):1325–1335
 4. Seckl JR, Chapman KE (1997) Medical and physiological aspects 
of the 11beta-hydroxysteroid dehydrogenase system. Eur J Bio-
chem 249(2):361–364
 5. Stewart PM, Toogood AA, Tomlinson JW (2001) Growth hor-
mone, insulin-like growth factor-I and the cortisol-cortisone shut-
tle. Horm Res 56(Suppl 1):1–6
 6. Gelding SV, Taylor NF, Wood PJ, Noonan K, Weaver JU, Wood 
DF, Monson JP (1998) The effect of growth hormone replacement 
therapy on cortisol-cortisone interconversion in hypopituitary 
adults: evidence for growth hormone modulation of extrarenal 
11 beta-hydroxysteroid dehydrogenase activity. Clin Endocrinol 
(Oxf) 48(2):153–162
 7. Weaver JU, Thaventhiran L, Noonan K, Burrin JM, Taylor NF, 
Norman MR, Monson JP (1994) The effect of growth hormone 
replacement on cortisol metabolism and glucocorticoid sensitivity 
in hypopituitary adults. Clin Endocrinol (Oxf) 41(5):639–648
 8. Walker BR, Andrew R, MacLeod KM, Padfield PL (1998) Growth 
hormone replacement inhibits renal and hepatic 11 beta-hydrox-
ysteroid dehydrogenases in ACTH-deficient patients. Clin Endo-
crinol (Oxf) 49(2):257–263
 9. Paulsen SK, Pedersen SB, Jørgensen JO, Fisker S, Christiansen 
JS, Flyvbjerg A, Richelsen B (2006) Growth hormone (GH) sub-
stitution in GH-deficient patients inhibits 11beta-hydroxysteroid 
dehydrogenase type 1 messenger ribonucleic acid expression in 
adipose tissue. J Clin Endocrinol Metab 91(3):1093–1098
 10. Maghnie M, Triulzi F, Larizza D, Preti P, Priora C, Scotti G, Severi 
F (1991) Hypothalamic-pituitary dysfunction in growth hormone-
deficient patients with pituitary abnormalities. J Clin Endocrinol 
Metab 73(1):79–83
 11. Giavoli C, Libé R, Corbetta S, Ferrante E, Lania A, Arosio M, 
Spada A, Beck-Peccoz P (2004) Effect of recombinant human 
 J Endocrinol Invest
1 3
growth hormone (GH) replacement on the hypothalamic-pituitary-
adrenal axis in adult GH-deficient patients. J Clin Endocrinol Metab 
89(11):5397–5401
 12. Marshall WA, Tanner JM (1969) Variations in pattern of pubertal 
changes in girls. Arch Dis Child 44:291
 13. Growth Hormone Research Society (2000) Consensus guidelines 
for the diagnosis and treatment of growth hormone (GH) defi-
ciency in childhood and adolescence: summary statement of the GH 
Research Society. GH Research Society. J Clin Endocrinol Metab 
85:3990–3993
 14. Anderson M (1971) Use of the Greulich-Pyle ‘radiographic atlas of 
skeletal development of the hand and wrist’ in a clinical context. Am 
J Phys Anthropol 35(3):347–352
 15. Ciresi A, Cicciò F, Amato MC, Giordano C (2015) Revaluation of 
the clinical and metabolic behavior of children with isolated growth 
hormone deficiency during GH treatment according to newly pro-
posed note 39 of the Italian Medicines Agency (AIFA). J Endocrinol 
Invest 38(12):1301–1307
 16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, 
Turner RC (1985) Homeostasis model assessment: insulin resist-
ance and beta-cell function from fasting plasma glucose and insulin 
concentrations in man. Diabetologia 28:412–419
 17. Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices 
obtained from oral glucose tolerance testing: comparison with the 
euglycemic insulin clamp. Diabetes Care 22:1462–1470
 18. Lange M, Feldt-Rasmussen U, Svendsen OL, Kastrup KW, Juul A, 
Müller J (2003) High risk of adrenal insufficiency in adults previ-
ously treated for idiopathic childhood onset growth hormone defi-
ciency. J Clin Endocrinol Metab 88(12):5784–5789
 19. Böttner A, Keller E, Kratzsch J, Stobbe H, Weigel JF, Keller A, 
Hirsch W, Kiess W, Blum WF, Pfäffle RW (2004) PROP1 mutations 
cause progressive deterioration of anterior pituitary function includ-
ing adrenal insufficiency: a longitudinal analysis. J Clin Endocrinol 
Metab 89(10):5256–5265
 20. di Iorgi N, Secco A, Napoli F, Tinelli C, Calcagno A, Fratangeli N, 
Ambrosini L, Rossi A, Lorini R, Maghnie M (2007) Deterioration 
of growth hormone (GH) response and anterior pituitary function 
in young adults with childhood-onset GH deficiency and ectopic 
posterior pituitary: a two-year prospective follow-up study. J Clin 
Endocrinol Metab 92(10):3875–3884
 21. Moore JS, Monson JP, Kaltsas G, Putignano P, Wood PJ, Shep-
pard MC, Besser GM, Taylor NF, Stewart PM (1999) Modulation of 
11beta-hydroxysteroid dehydrogenase isozymes by growth hormone 
and insulin-like growth factor: in vivo and in vitro studies. J Clin 
Endocrinol Metab 84(11):4172–4177
 22. Giavoli C, Bergamaschi S, Ferrante E, Ronchi CL, Lania AG, 
Rusconi R, Spada A, Beck-Peccoz P (2008) Effect of growth hor-
mone deficiency and recombinant hGH (rhGH) replacement on the 
hypothalamic-pituitary-adrenal axis in children with idiopathic iso-
lated GH deficiency. Clin Endocrinol (Oxf) 68(2):247–251
 23. Walvoord EC, Rosenman MB, Eugster EA (2004) Preva-
lence of adrenocorticotropin deficiency in children with idi-
opathic growth hormone deficiency. J Clin Endocrinol Metab 
89(10):5030–5034
 24. August GP, Lippe BM, Blethen SL, Rosenfeld RG, Seelig SA, 
Johanson AJ, Compton PG, Frane JW, McClellan BH, Sher-
man BM (1990) Growth hormone treatment in the United States: 
demographic and diagnostic features of 2331 children. J Pediatr 
116(6):899–903
 25. Savas Erdeve S, Ocal G, Berberoglu M, Siklar Z, Hacihamdioglu 
B (2011) Is adrenocorticotropic hormone deficiency really rare in 
patients with idiopathic growth hormone deficiency and normal 
thyroid function tests? Horm Res Paediatr 75(3):200–205
 26. Nieman LK (2003) Dynamic evaluation of adrenal hypofunction. J 
Endocrinol Invest 26(7 Suppl):74–82
 27. Erturk E, Jaffe CA, Barkan AL (1998) Evaluation of the integrity 
of the hypothalamic-pituitary-adrenal axis by insulin hypoglycemia 
test. J Clin Endocrinol Metab 83(7):2350–2354
 28. Grinspoon SK, Biller BM (1994) Clinical review 62: laboratory 
assessment of adrenal insufficiency. J Clin Endocrinol Metab 
79(4):923–931
 29. Weintrob N, Sprecher E, Josefsberg Z, Weininger C, Aurbach-Klip-
per Y, Lazard D, Karp M, Pertzelan A (1998) Standard and low-dose 
short adrenocorticotropin test compared with insulin-induced hypo-
glycemia for assessment of the hypothalamic-pituitary-adrenal axis 
in children with idiopathic multiple pituitary hormone deficiencies. 
J Clin Endocrinol Metab 83(1):88–92
 30. Rasmuson S, Olsson T, Hagg E (1996) A low dose ACTH test to 
assess the function of the hypothalamic-pituitary-adrenal axis. Clin 
Endocrinol (Oxf) 44(2):151–156
 31. Ambrosi B, Barbetta L, Re T, Passini E, Faglia G (1998) The one 
microgram adrenocorticotropin test in the assessment of hypotha-
lamic-pituitary-adrenal function. Eur J Endocrinol 139(6):575–579
 32. Kazlauskaite R, Maghnie M (2010) Pitfalls in the diagnosis of cen-
tral adrenal insufficiency in children. Endocr Dev 17:96–107
 33. Maghnie M, Uga E, Temporini F, Di Iorgi N, Secco A, Tinelli C, 
Papalia A, Casini MR, Loche S (2005) Evaluation of adrenal func-
tion in patients with growth hormone deficiency and hypothalamic-
pituitary disorders: comparison between insulin-induced hypogly-
cemia, low-dose ACTH, standard ACTH and CRH stimulation tests. 
Eur J Endocrinol 152(5):735–741
 34. di Iorgi N, Napoli F, Allegri A, Secco A, Calandra E, Calcagno A, 
Frassinetti C, Ghezzi M, Ambrosini L, Parodi S, Gastaldi R, Loche 
S, Maghnie M (2010) The accuracy of the glucagon test compared to 
the insulin tolerance test in the diagnosis of adrenal insufficiency in 
young children with growth hormone deficiency. J Clin Endocrinol 
Metab 95(5):2132–2139
 35. Qing L, Wei R, Chan L, Xiaoya Z, Xin X (2017) Sensitivity of vari-
ous body indices and visceral adiposity index in predicting meta-
bolic syndrome among Chinese patients with adult growth hormone 
deficiency. J Endocrinol Invest 40(6):653–661
 36. Feelders RA, Pulgar SJ, Kempel A, Pereira AM (2012) The bur-
den of Cushing’s disease: clinical and health-related quality of life 
aspects. Eur J Endocrinol 167(3):311–326
 37. Wang L, Wang Q, Li G, Liu W (2015) Dynamic changes in the 
hypothalamic-pituitary-adrenal axis during growth hormone therapy 
in children with growth hormone deficiency: a multicenter retrospec-
tive study. J Pediatr Endocrinol Metab 28(9–10):975–979
 38. Capalbo D, Mattace Raso G, Esposito A, Di Mase R, Barbieri F, 
Meli R, Bruzzese D, Salerno M (2013) Cluster of cardiometabolic 
risk factors in children with GH deficiency: a prospective, case-
control study. Clin Endocrinol (Oxf) 80(6):856–862
 39. Ciresi A, Amato MC, Giordano C (2015) Reduction in insulin sen-
sitivity and inadequate β-cell capacity to counteract the increase in 
insulin resistance in children with idiopathic growth hormone defi-
ciency during 12 months of growth hormone treatment. J Endocrinol 
Invest 38(3):351–359
 40. Ciresi A, Amato MC, Criscimanna A, Mattina A, Vetro C, Galluzzo 
A, D’Acquisto G, Giordano C (2007) Metabolic parameters and adi-
pokine profile during GH replacement therapy in children with GH 
deficiency. Eur J Endocrinol 156(3):353–360
 41. Ciresi A, Pizzolanti G, Leotta M, Guarnotta V, Teresi G, Giordano 
C (2016) Resistin, visfatin, leptin and omentin are differently related 
to hormonal and metabolic parameters in growth hormone-deficient 
children. J Endocrinol Invest 39(9):1023–1030
 42. Yuen KC, Roberts CT Jr, Frystyk J, Rooney WD, Pollaro JR, 
Klopfenstein BJ, Purnell JQ (2014) Short-term, low-dose GH 
therapy improves insulin sensitivity without modifying cortisol 
metabolism and ectopic fat accumulation in adults with GH defi-
ciency. J Clin Endocrinol Metab 99(10):E1862–E1869
